UTA has acquired JUV Consulting, a marketing, creative services and research agency that helps clients target Gen Z consumers.

JUV-161 is the lead therapeutic candidate discovered by JuvNET, which screens Juvena’s proprietary protein library of human stem-cell secreted proteins with therapeutic potential using unbiased ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year.

End incontinence instantly with an easy, non-invasive treatment at V-Juv ( (SL Advertiser)) V-Juv offers up a simple solution for men and women who suffer from incontinence.

UTA is expanding its marketing division, acquiring JUV Consulting, a company that specializes in connecting brands with Gen Z and youth culture.

UTA buys Gen Z-focused consultancy amid marketing services expansion JUV, which was founded by Gen Zers and has worked with clients including Google and Unilever, will be renamed Next Gen.

JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult ...

JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered using Juvena’s proprietary JuvNET platform ...